For decades, Polycystic Ovary Syndrome, widely known as PCOS, has been one of the most common yet frequently misunderstood conditions in women’s health. Today, the scientific community is moving toward a new name: PMOS, Polyendocrine Metabolic Ovarian Syndrome.
This change is not simply a matter of terminology. It reflects a deeper evolution in the way the syndrome is understood, communicated and managed.
Why PCOS Is Being Renamed PMOS
The term PCOS has long placed the focus on the ovaries and on the presence of “cysts”, even though the condition is much broader. In many women, the syndrome involves a complex interaction between hormonal imbalance, insulin dysfunction, metabolic alterations, reproductive health, dermatological manifestations and long-term cardiometabolic risk.
The new name, Polyendocrine Metabolic Ovarian Syndrome, offers a more accurate description of this complexity. It highlights the endocrine and metabolic dimensions of the condition, helping to move beyond a limited ovarian interpretation and toward a more systemic view of women’s health.
A Broader View of Women’s Endocrine and Metabolic Health
This shift is particularly important because naming a condition correctly can influence awareness, diagnosis and care. A broader definition may help healthcare professionals adopt a more integrated approach, while also helping patients better understand the origin of their symptoms and the importance of long-term management.
The evolution from PCOS to PMOS has also been discussed by EGOI-PCOS, which welcomed the new terminology as an important step toward recognising the systemic nature of the syndrome. In its scientific perspective, EGOI-PCOS underlines how insulin resistance, hyperinsulinemia, chronic low-grade inflammation and metabolic dysfunction should not be considered secondary aspects, but key biological drivers of the condition. Read more in the EGOI-PCOS perspective on the new name for PCOS.
What the Transition from PCOS to PMOS Means
The transition from PCOS to PMOS also opens a broader scientific conversation. While the new name represents a significant step forward, the debate continues on how best to describe a syndrome that affects women across different stages of life and requires a multidisciplinary, long-term vision.
At Lo.Li. Pharma International, we believe this change marks an important advancement in women’s health communication. Recognising the full endocrine-metabolic profile of the syndrome means supporting a more precise, evidence-based and patient-centred approach.
The transition from PCOS to PMOS is therefore more than a new acronym. It is a step toward a more complete scientific identity: one that better reflects the complexity of the condition and the need to look at women’s health through a wider, integrated and long-term perspective.
